Why did BioNTech lower its 2026 sales outlook, and what is the new revenue range?

BioNTech lowered its 2026 sales outlook due to softer-than-expected COVID-19 vaccine demand, the use of existing vaccine stockpiles in Germany, and the deferral of milestone payments. The company revised its full-year 2026 revenue guidance to €1.6 billion–€1.9 billion ($1.84 billion–$2.19 billion), down from its previous March forecast of €2 billion–€2.3 billion.

How did BioNTech's Q2 2024 financial performance compare to Q2 2023, and what was its net loss for the quarter?

BioNTech's quarterly revenue slumped to €105.6 million in Q2 2024, down from €260.8 million in Q2 2023 — a decline of more than half — while its net loss expanded to €820.8 million for the quarter ended June 2024, more than double the prior-year loss.

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

Aug 4, 2026

BioNTech reduced its 2026 revenue guidance to €1.6-1.9 billion due to softening COVID vaccine demand, with Q2 revenue falling over 50%. The German pharma company also appointed a new CEO and plans to cut R&D spending following a doubled quarterly net loss.

reuters

2026-08-04

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

FAQ